

## Ribosomal Synthesis of Dehydroalanine-Containing Peptides

Florian P. Seebeck and Jack W. Szostak\*

Howard Hughes Medical Institute and Center for Computational and Integrative Biology, Simches Research Center, Massachusetts General Hospital, 185 Cambridge Street, Boston, Massachusetts 02114


Received February 9, 2006; E-mail: szostak@molbio.mgh.harvard.edu

The nonribosomal peptides (NRP) feature an enormous chemical diversity and have given rise to a multitude of therapeutics.<sup>1</sup> However, their microbial synthesis by large multifunctional synthetases complicates the construction and sampling of large libraries of novel NRPs.<sup>2</sup> In contrast, peptides synthesized by ribosomal translation are amenable to ultrahigh throughput screening schemes, such as mRNA display,<sup>3</sup> a combinatorial method that allows the sampling of more than  $10^{13}$  individual molecules.<sup>4</sup> In the past, however, these peptide libraries had to be constructed from the 20 canonical L-amino acids—a rather uniform set of building blocks compared to the variety of L-, D-,  $\beta$ -, and N-methyl and  $\alpha,\beta$ -unsaturated amino acids from which NRPs are tailored. In an effort to reduce this limitation, we and others have shown that the in vitro translation of nonbiological polymers from unnatural L-amino acids is indeed possible with a reconstituted *Escherichia coli* translation system (PURE-system).<sup>5–7</sup> However, the ribosomal production of polymers with additional alternative backbone residues remains a challenging,<sup>8–10</sup> yet indispensable step toward the production of NRP-like structures in an mRNA-templated fashion.

One backbone alteration found in many natural products, such as lantibiotics,<sup>11</sup> microcystin,<sup>12</sup> and thiopeptide antibiotics,<sup>13</sup> stems from the incorporation of dehydroalanine ( $\Delta$ Ala, Scheme 1).  $\alpha,\beta$ -Unsaturated amino acids exhibit rigidifying effects on the peptide backbone, which stabilizes secondary structures and increases the proteolytic stability of the parent molecule.<sup>14</sup> Due to its moderate electrophilicity,  $\Delta$ Ala may also serve as a warhead in protein-reactive compounds<sup>15</sup> and has proven to be a valuable intermediate for the preparation of cyclized, glycosylated, or prenylated peptides through intra- or intermolecular Michael addition.<sup>16</sup>

To harness this versatility for the in vitro selection of peptides, we devised a method for constructing dehydropeptides through mRNA-templated, ribosomal peptide synthesis. Van der Donk et al. reported the use of Se-phenylselenocysteine (SecPh) as a building block for solid-phase peptide synthesis that can be converted to  $\Delta$ Ala via oxidative elimination.<sup>17</sup> The chemical conditions for this process are compatible with biomacromolecules; however, SecPh is not a reported substrate for any of the *E. coli* aminoacyl tRNA synthetases and thus cannot be used for all-enzymatic peptide synthesis. To circumvent this problem, we investigated the possibility that selenalysine<sup>18</sup> ( $K_{Se}$ , Scheme 1) might be an efficient substrate for lysine aminoacyl tRNA synthetase and thus be incorporated into peptides as directed by lysine codons on translated mRNAs. We further surmised that such selenopeptides might undergo oxidative elimination to expose  $\Delta$ Ala in a post-translational manner (Scheme 1).

To test these ideas, we assembled a reconstituted translation system from *E. coli*<sup>6</sup> as previously described and tested the efficiency of  $K_{Se}$ <sup>19,20</sup> incorporation in place of lysine into a short peptide (Figure 1, peptide 1). Fifty microliter translation reactions containing the corresponding mRNA were incubated for 1 h at 37 °C. Product peptide yields were determined by purification on NTA-





**Figure 1.** Selenalysine incorporation assay. Left: The efficiency of peptide 1 production was determined by scintillation counting of specific <sup>35</sup>S-Met activity. The bars represent the average of three independent measurements, and the averaged value for the lysine-containing reactions ( $35 \pm 3$  pmol) was set to 100%. Control translation reactions without supplemented lysine (no lysine) show a significant background due to the presence of contaminating lysine in the translation mixture. Right: MALDI-TOF analysis of the peptide 2 after translation (A,  $m_{\text{calc}} = 1883.6$  Da), oxidative elimination (B,  $m_{\text{calc}} = 1524.6$  Da), and Michael addition of L-cysteine (C,  $m_{\text{calc}} = 1887.7$  Da). Signals consistent with the production of peptides containing one (a) or two (b) lysines are indicated. To improve detectability by MALDI-TOF, peptides 1 and 2 were produced as the free N-terminal amine by omission of the formyl donor (10-formyl-5,6,7,8-tetrahydrofolic acid) necessary for formylation of methionyl tRNA.

agarose beads and <sup>35</sup>S-Met scintillation counting (Figure 1, left). Reactions supplemented with 0.2 mM lysine typically yielded 30–40 pmol of peptide. Reactions where lysine was replaced by 0.16 mM  $K_{Se}$  produced similar amounts of product, which was subsequently identified as the desired selenopeptide by MALDI-TOF MS ( $m_{\text{obs}} = 1494.8$  Da vs  $m_{\text{calc}} = 1494.6$  Da). As judged by this analysis, the  $K_{Se}$ -containing reaction did not incorporate lysine. This is notable since endogenous traces of lysine in the translation mixture allow considerable synthesis of the lysine-containing peptide ( $m_{\text{obs}} = 1428.6$  Da vs  $m_{\text{calc}} = 1428.7$  Da) (Figure 1, left).

As a more rigorous test of the efficiency and fidelity of lysine replacement by  $K_{Se}$ , we prepared an mRNA containing three consecutive lysine codons. This template was also efficiently translated into selenopeptide (30 pmol/50  $\mu$ L) with an observed mass of  $m_{\text{obs}} = 1883.2$  Da ( $m_{\text{calc}} = 1883.6$  Da), indicating that

### Scheme 1





**Figure 2.** Incorporation of  $\Delta$ Ala into a cyclic scaffold. Two concomitant  $S_N2$  reactions between two peptide-borne thiols (A,  $m_{\text{calc}} = 1923.7$  Da) and one equivalent of  $\alpha, \alpha'$ -dibromo-*m*-xylene lead to peptide cyclization. Possible side products, such as the linear adduct of two equivalents of xylene and one peptide, are not observed (B,  $m_{\text{calc}} = 1900.8$  Da). A minor signal 16 Da higher than the expected mass indicates partial sulfoxidation of the newly formed thioethers by the conditions used for  $\Delta$ Ala formation.

incorporation of K<sub>Se</sub> does not significantly inhibit the translational machinery and that lysine incorporation is effectively outcompeted (Figure 1A).

Translated and purified selenopeptide (Figure 1, peptide 2) was then converted into the corresponding dehydropeptide by incubation with 200 mM H<sub>2</sub>O<sub>2</sub> at pH 5–6 on ice for 1 h.<sup>17</sup> The mass difference between starting material and the oxidized peptide as determined by MALDI-TOF is consistent with elimination of three formal equivalents of 2-amino ethylselenol ( $-3 \times 125$  Da) accompanied by sulfoxidation of the N-terminal methionine (+16) (Figure 1B). The formation of three electrophilic functions was further confirmed by intermolecular thiol conjugation by incubating the oxidized peptide with 100 mM L-cysteine (Figure 1C). Indeed, a large variety of nucleophiles may be reacted with  $\Delta$ Ala-containing peptides, and thus our approach presents a general method for the site-directed incorporation of small molecules into translated peptides or proteins.<sup>16</sup>

Finally, we aimed at introducing  $\Delta$ Ala into cyclic peptides so as to enhance our mimicry of  $\Delta$ Ala-containing natural products and ultimately set the stage for the *in vitro* selection of novel, drug-like molecules. Biologically active peptides are very often cyclic because cyclization improves proteolytic stability,<sup>21</sup> membrane solubility,<sup>22</sup> and target affinity/specificity.<sup>23</sup> We exploited the recent discovery that  $\alpha, \alpha'$ -dibromo-*m*-xylene can cross-link and therefore cyclize peptides that contain two cysteine residues.<sup>24</sup> The two resulting thioether bonds are stable, apolar, and may improve bioavailability.

A model peptide (Figure 2, peptide 3) was produced by *in vitro* translation and adsorbed onto NTA-agarose beads. These beads were then treated with 5 mM  $\alpha, \alpha'$ -dibromo-*m*-xylene and 0.2 mM tris(carboxyethyl)phosphine in a 1:4 acetonitrile:50 mM Tris-HCl buffer, pH 8.0 for 1 h at room temperature. The peptides were then eluted with 0.2% TFA and oxidized with 20 mM H<sub>2</sub>O<sub>2</sub> at pH 5.0 for 1 h and then analyzed by MALDI-TOF (Figure 2B). The observed mass is consistent with the desired structure with a minor signal consistent with sulfoxidation of one of the two thioethers.

Treatment of the same peptide with 200 mM H<sub>2</sub>O<sub>2</sub> led to a mixture of non-, mono-, and disulfoxidized species. Reduction of the oxidant concentration, however, led to satisfactory homogeneity. For the same reason, we chose to substitute methionine with norleucine (M<sub>Nor</sub>), an efficient analogue with an oxidation-resistant side chain.<sup>25</sup>

In summary, we have demonstrated the production of genetically encoded dehydropeptides. Our approach employs unmodified components from the translation machinery of *E. coli* and mild but robust conditions to install multiple electrophilic functions in linear or cyclic peptides. The simplicity of this methodology should allow wide applicability, making highly decorated peptides available independently of solid-phase peptide synthesis. Furthermore, having introduced  $\Delta$ Ala to the toolbox of mRNA-templated peptide synthesis, we may now embark on ultrahigh throughput selections for specific protein-reactive or catalytically active compounds.

**Acknowledgment.** We thank Drs. M. C. T. Hartman, K. Josephson, and B. Seelig for their insightful advice. J.W.S. is an Investigator of the Howard Hughes Medical Institute, and F.P.S. is supported by the National Institutes of Health (GM 074505-02).

**Supporting Information Available:** Experimental details. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## References

- Walsh, C. T. *Antibiotics, Actions, Origins, Resistance*; ASM Press: Washington, DC, 2003.
- Finking, R.; Marahiel, M. A. *Annu. Rev. Microbiol.* **2004**, *58*, 453–488.
- Roberts, R. W.; Szostak, J. W. *Proc. Natl. Acad. Sci. U.S.A.* **1997**, *94*, 12297–12302.
- Keefe, A. D.; Szostak, J. W. *Nature* **2001**, *410*, 715–718.
- Shimizu, Y.; Inoue, A.; Tomari, Y.; Suzuki, T.; Yokogawa, T.; Nishikawa, K.; Ueda, T. *Nat. Biotechnol.* **2001**, *19*, 751–755.
- Josephson, K.; Hartman, M. C. T.; Szostak, J. W. *J. Am. Chem. Soc.* **2005**, *127*, 11727–11735.
- Forster, A. C.; Tan, Z.; Nalam, M. N. L.; Lin, H.; Qu, H.; Cornish, V. W.; Blacklow, S. C. *Proc. Natl. Acad. Sci. U.S.A.* **2003**, *100*, 6353–6357.
- Tan, Z.; Forster, A. C.; Blacklow, S. C.; Cornish, V. W. *J. Am. Chem. Soc.* **2004**, *126*, 12752–12753.
- Dedkova, L. M.; Fahmi, N. E.; Golovine, S. Y.; Hecht, S. M. *J. Am. Chem. Soc.* **2003**, *125*, 6616–6617.
- Eisenhauer, B. M.; Hecht, S. M. *Biochemistry* **2002**, *41*, 11472–11478.
- Chatterjee, C.; Paul, M.; Xie, L. L.; van der Donk, W. A. *Chem. Rev.* **2005**, *105*, 633–683.
- MacKintosh, R. W.; Dalby, K. N.; Campbell, D. G.; Cohen, P. T. W.; Cohen, P.; MacKintosh, C. *FEBS Lett.* **1995**, *371*, 236–240.
- Bagley, M. C.; Dale, J. W.; Merritt, E. A.; Xiong, A. *Chem. Rev.* **2005**, *105*, 685–714.
- Humphrey, J. M.; Chamberlin, A. R. *Chem. Rev.* **1997**, *97*, 2243–2266.
- Drahl, C.; Cravatt, B. F.; Sorensen, E. J. *Angew. Chem., Int. Ed.* **2005**, *44*, 5788–5809.
- Gieselmann, M. D.; Zhu, Y. T.; Zhou, H.; Galonic, D.; van der Donk, W. A. *ChemBiochem* **2002**, *3*, 709–716.
- Okeley, N. M.; Zhu, Y. T.; van der Donk, W. A. *Org. Lett.* **2000**, *2*, 3603–3606.
- De Marco, C.; Busiello, V.; Digirolamo, M.; Cavallini, D. *Biochim. Biophys. Acta* **1976**, *454*, 298–308.
- The synthesis of K<sub>Se</sub> has been described before (ref 20). K<sub>Se</sub> synthesized from sodium borohydride reduced L-selenocysteine, and 2-bromoethylamine was characterized by MS (EI)  $m/z$  (M + H)<sup>+</sup> 213.0.
- De Marco, C.; Rinaldi, A.; Dermeni, S.; Cavallini, D. *Gazz. Chim.* **1975**, *105*, 1113–1115.
- March, D. R.; Abbenante, G.; Bergman, D. A.; Brinkworth, R. I.; Wickramasinghe, W.; Begun, J.; Martine, J. L.; Fairlie, D. P. *J. Am. Chem. Soc.* **1996**, *118*, 3375–3379.
- Burton, P. S.; Conradi, R. A.; Ho, N. F. H.; Hilgers, A. R.; Borchardt, R. T. *J. Pharm. Sci.* **1996**, *85*, 1336–1340.
- Khan, A. R.; Parrish, J. C.; Fraser, M. E.; Smith, W. W.; Bartlett, P. A.; James, M. N. *Biochemistry* **1998**, *37*, 16839–16845.
- Timmerman, P.; Beld, J.; Puijk, W. C.; Meloen, R. H. *ChemBiochem* **2005**, *6*, 821–824.
- Kiick, K. L.; Weberskirch, R.; Tirrell, D. A. *FEBS Lett.* **2001**, *502*, 25–30.

JA060966W